HIV drug resistance testing by high-multiplex "Wide" sequencing on the MiSeq instrument

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 6824-6833

  Lapointe, H R ^a   Dong, W ^a   Lee, G Q ^a   Bangsberg, D R ^b,c,d   Martin, J N ^e   Mocello, A R ^e   Boum, Y ^d   Karakas, A ^a   Kirkby, D ^a   Poon, A F Y ^a,f   Harrigan, P R ^a,f   Brumme, C J ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NUCLEOTIDE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

AMPLICON; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BIOCHEMICAL EQUIPMENT; CANADIAN; CODON; CONSENSUS SEQUENCE; CONTROLLED STUDY; FEASIBILITY STUDY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEASUREMENT ACCURACY; MISEQ INSTRUMENT; MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUALITY CONTROL; SANGER SEQUENCING; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; VIRUS LOAD; CANADA; DRUG EFFECTS; GENETICS; GENOTYPING TECHNIQUE; HUMAN IMMUNODEFICIENCY VIRUS 1;

CANADA; DRUG RESISTANCE, VIRAL; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; VIRAL LOAD;

EID: 84946231661     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01490-15     Document Type: Article

References (45)

1. Lima VD, Hogg RS, Harrigan P.R., Moore D., Yip B, Wood E, Montaner JSG. 2007. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21:685-692. http://dx.doi.org/10.1097/QAD.0b013e32802ef30c.
2. Samji H, Cescon A, Hogg R.S., Modur SP, Althoff KN, Buchacz K, Burchell A.N., Cohen M., Gebo KA, Gill MJ, Justice A, Kirk G., Klein MB, Korthuis PT, Martin J, Napravnik S., Rourke SB, Sterling TR, Silverberg MJ, Deeks S, Jacobson LP, Bosch RJ, Kitahata MM, Goedert JJ, Moore R, Gange SJ. 2013. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 8:e81355. http://dx.doi.org/10.1371/journal.pone.0081355.
3. Montaner JSG, Hogg R, Wood E., Kerr T, Tyndall M, Levy A.R., Harrigan PR. 2006. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368:531-536. http://dx.doi.org/10.1016/S0140-6736(06)69162-9.
4. Montaner JSG, Lima VD, Barrios R, Yip B., Wood E, Kerr T, Shannon K., Harrigan PR, Hogg RS, Daly P, Kendall P. 2010. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 376:532-539. http://dx.doi.org/10.1016/S0140-6736(10)60936-1.
5. Montaner JSG, Lima VD, Harrigan P.R., Lourenço L, Yip B., Nosyk B, Wood E, Kerr T., Shannon K, Moore D, Hogg R.S., Barrios R., Gilbert M, Krajden M, Gustafson R, Daly P, Kendall P. 2014. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. PLoS One 9:e87872. http://dx.doi.org/10.1371/journal.pone.0087872.
6. Cohen MS, Chen YQ, McCauley M, Gamble T., Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B., Pilotto JHS, Godbole SV, Mehendale S, Chariyalertsak S., Santos BR, Mayer KH, Hoffman IF, Eshleman S.H., Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR. 2011. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365:493-505. http://dx.doi.org/10.1056/NEJMoa1105243.
7. Baxter JD, Mayers DL, Wentworth D.N., Neaton JD, Hoover ML, Winters MA, Mannheimer S.B., Thompson MA, Abrams DI, Brizz BJ, Ioannidis J.P., Merigan TC, CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14:F83-F93. http://dx.doi.org/10.1097/00002030-200006160-00001.
8. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A., Ait-Khaled M, Baxter J, Clevenbergh P., Hammer S, Harrigan R, Katzenstein D., Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 5:41-48.
9. Bennett DE, Bertagnolio S, Sutherland D., Gilks CF. 2008. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 13(Suppl 2):1-13.
10. Gupta RK, Jordan MR, Sultan B.J., Hill A., Davis DHJ, Gregson J, Sawyer A.W., Hamers RL, Ndembi N, Pillay D, Bertagnolio S. 2012. Global trendsinantiretroviral resistance intreatment-naïve individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 380:1250-1258. http://dx.doi.org/10.1016/S0140-6736(12)61038-1.
11. Hamers RL, Wallis CL, Kityo C, Siwale M., Mandaliya K, Conradie F, Botes M.E., Wellington M., Osibogun A, Sigaloff KCE, Nankya I, Schuurman R., Wit FW, Stevens WS, van Vugt M, de Wit TFR. 2011. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11:750-759. http://dx.doi.org/10.1016/S1473-3099(11)70149-9.
12. Gill VS, Lima VD, Zhang W, Wynhoven B., Yip B, Hogg RS, Montaner JSG, Harrigan PR. 2010. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 50:98-105. http://dx.doi.org/10.1086/648729.
13. Rhee S-Y, Blanco J.L., Jordan MR, Taylor J, Lemey P, Varghese V., Hamers RL, Bertagnolio S, de Wit TFR, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CAB, Brumme ZL, Busch MP, Bussmann H, Chaix M-L, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong H-HM, van de Vijver DAMC, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JPA, Vandamme A-M, Shafer RW. 2015. Geographic and temporal trends inthe molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med 12:e1001810. http://dx.doi.org/10.1371/journal.pmed.1001810.
14. Liu TF, Shafer RW 2006. Web resources for HIV type 1 genotypicresistance test interpretation. Clin Infect Dis 42:1608-1618. http://dx.doi.org/10.1086/503914.
15. Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L., Picchio G, Lecocq P. 2007. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 145: 47-55. http://dx.doi.org/10.1016/j.jviromet.2007.05.009.
16. Cunningham S, Ank B, Lewis D., Lu W, Wantman M, Dileanis J., Jackson JB, Palumbo P, Krogstad P, Eshleman SH 2001. Performance of the Applied Biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol 39:1254-1257. http://dx.doi.org/10.1128/JCM.39.4.1254-1257.2001.
17. Schuurman R, Brambilla D, de Groot T, Huang D, Land S., Bremer J, Benders I, Boucher CAB. 2002. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 18:243-248. http://dx.doi.org/10.1089/088922202753472801.
18. Korn K, Reil H, Walter H., Schmidt B. 2003. Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results. J Clin Microbiol 41:3559-3565. http://dx.doi.org/10.1128/JCM.41.8.3559-3565.2003.
19. Church JD, Jones D, Flys T., Hoover D, Marlowe N, Chen S., Shi C, Eshleman JR, Guay L.A., Jackson JB, Kumwenda N, Taha TE, Eshleman SH 2006. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 8:430-432. http://dx.doi.org/10.2353/jmoldx.2006.050148.
20. Simen BB, Simons JF, Hullsiek K.H., Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C., Turenchalk GS, Braverman MS, Desany B, Rothberg J.M., Egholm M., Kozal MJ. 2009. Low-abundance drugresistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 199:693-701. http://dx.doi.org/10.1086/596736.
21. Ram D, Leshkowitz D, Gonzalez D., Forer R, Levy I, Chowers M., Lorber M, Hindiyeh M, Mendels on E, Mor O. 2015. Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratory. J Virol Methods 212:12-16. http://dx.doi.org/10.1016/j.jviromet.2014.11.003.
22. Barzon L, Lavezzo E, Militello V., Toppo S, Palù G. 2011. Applications of next-generation sequencing technologies to diagnostic virology. Int J Mol Sci 12:7861-7884. http://dx.doi.org/10.3390/ijms12117861.
23. Johnson JA, Li JF, Wei X, Lipscomb J., Irlbeck D, Craig C, Smith A., Bennett DE, Monsour M, Sandstrom P, Lanier E.R., Heneine W. 2008. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 5:e158. http://dx.doi.org/10.1371/journal.pmed.0050158.
24. Johnson JA, Geretti AM 2010. Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J Antimicrob Chemother 65:1322-1326. http://dx.doi.org/10.1093/jac/dkq139.
25. Paredes R, Lalama CM, Ribaudo H.J., Schackman BR, Shikuma C, Giguel F, Meyer W.A., Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR 2010. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 201: 662-671.
26. Li JZ, Kuritzkes DR 2013. Clinical implications of HIV-1 minority variants. Clin Infect Dis 56:1667-1674. http://dx.doi.org/10.1093/cid/cit125.
27. Li JZ. 2014. HIV-1 drug-resistant minority variants: sweating the small stuff. J Infect Dis 209:639-641. http://dx.doi.org/10.1093/infdis/jit656.
28. Ekici H, Rao SD, Sönnerborg A, Ramprasad V.L., Gupta R., Neogi U. 2014. Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries. J Antimicrob Chemother 69:3349-3355. http://dx.doi.org/10.1093/jac/dku278.
29. Dudley DM, Chin EN, Bimber B.N., Sanabani SS, Tarosso LF, Costa PR, Sauer M.M., Kallas EG, O'Connor DH. 2012. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One 7:e36494. http://dx.doi.org/10.1371/journal.pone.0036494.
30. Ji H, Massé N, Tyler S, Liang B, Li Y, Merks H, Graham M, Sandstrom P, Brooks J. 2010. HIV drug resistance surveillance using pooled pyrosequencing. PLoS One 5:e9263. http://dx.doi.org/10.1371/journal.pone.0009263.
31. Gall A, Ferns B, Morris C., Watson S, Cotten M, Robinson M., Berry N, Pillay D, Kellam P. 2012. Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J Clin Microbiol 50:3838-3844. http://dx.doi.org/10.1128/JCM.01516-12.
32. Lee GQ, Bangsberg DR, Muzoora C, Boum Y., Oyugi JH, Emenyonu N, Bennett J, Hunt P.W., Knapp D., Brumme CJ, Harrigan PR, Martin JN. 2014. Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. AIDS Res Hum Retroviruses 30:896-906. http://dx.doi.org/10.1089/aid.2014.0043.
33. Alexander CS, Dong W, Chan K., Jahnke N, O'Shaughnessy MV, Mo T, Piaseczny M.A., Montaner JS, Harrigan PR. 2001. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviralnaive individuals from a large North American cohort. AIDS 15:601-607. http://dx.doi.org/10.1097/00002030-200103300-00009.
34. Gonzalez-Serna A., Min JE, Woods C, Chan D., Lima VD, Montaner JSG, Harrigan PR, Swenson LC 2014. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis 58:1165-1173. http://dx.doi.org/10.1093/cid/ciu019.
35. Woods CK, Brumme CJ, Liu T.F., Chui CKS, Chu AL, Wynhoven B, Hall T.A., Trevino C., Shafer RW, Harrigan PR. 2012. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol 50:1936-1942. http://dx.doi.org/10.1128/JCM.06689-11.
36. Kozich JJ, Westcott SL, Baxter N.T., Highlander SK, Schloss PD. 2013. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol 79:5112-5120. http://dx.doi.org/10.1128/AEM.01043-13.
37. Langmead B, Salzberg SL 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9:357-359. http://dx.doi.org/10.1038/nmeth.1923.
38. Li H, Handsaker B, Wysoker A., Fennell T, Ruan J, Homer N., Marth G, Abecasis G, Durbin R. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078-2079. http://dx.doi.org/10.1093/bioinformatics/btp352.
39. Siepel AC, Halpern AL, Macken C, Korber BT 1995. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res Hum Retroviruses 11:1413-1416. http://dx.doi.org/10.1089/aid.1995.11.1413.
40. Johnson VA, Calvez V, Gunthard H.F., Paredes R., Pillay D, Shafer RW, Wensing A.M., Richman DD. 2013. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 21:6-14.
41. Bertagnolio S, Soto-Ramirez L, Pilon R., Rodriguez R, Viveros M, Fuentes L., Harrigan PR, Mo T, Sutherland D, Sandstrom P. 2007. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 12:107-113.
42. Hamers RL, Smit PW, Stevens W, Schuurman R., Rinke de Wit TF. 2009. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther 14:619-629.
43. Steegen K, Luchters S, Demecheleer E., Dauwe K, Mandaliya K, Jaoko W., Plum J, Temmerman M, Verhofstede C. 2007. Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots. J Clin Microbiol 45:3342-3351. http://dx.doi.org/10.1128/JCM.00814-07.
44. DeLong AK, Wu M, Bennett D., Parkin N, Wu Z, Hogan J.W., Kantor R. 2012. Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase. AIDS Res Hum Retroviruses 28:894-901. http://dx.doi.org/10.1089/aid.2011.0120.
45. Larder BA, Kohli A, Kellam P., Kemp SD, Kronick M, Henfrey RD. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673. http://dx.doi.org/10.1038/365671a0.